The end of the year is here!We would like to thank you for your interest and trust!Our team wishes you a wonderful festive season and remains at your disposal during this period.

The continued availability of medicines is one of the most important priorities for EU authorities. Indeed, shortages or other problems with the availability of medicinal products create challenges for the medicine supply chain an

The French National Agency for the Safety of Medicines and Health Products (ANSM) has updated on 08/08/2022 its guidelines for the determination of financial penalties in case of non-compliance of pharmaceutical companies with the

Having a Business Continuity Plan (BCP) would have enabled many companies to cope much better with the crisis linked to the COVID-19.Indeed, the Business Continuity Plan (BCP) makes it possible to anticipate problems likely the di

The Qualified Person (QP) a key function in the French pharmaceutical companies The Qualified Person is a privileged function in France. Placed at the heart of the board of directors of the French pharmaceutica